In summary, herein, we demonstrated that quercetin is a potential therapeutic and/or adjuvant agent for the treatment of NSCLC harboring EGFR-L858R/T790M/C797S mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.